Chlamydia

  1. Overview
  2. Epidemiology
  3. Pathophysiology
  4. Sites of Infection and Clinical Presentation
  5. Lymphogranuloma Venereum (LGV)
  6. Complications
  7. Diagnosis
  8. Treatment
  9. Prevention
  10. Research Advances
  11. Key Research Papers
  12. PubMed Research Papers
  13. Connections

Overview

Chlamydia is the most common reportable bacterial sexually transmitted infection (STI) in the United States — and possibly the most common bacterial STI in the world. It is caused by Chlamydia trachomatis serovars D through K, a tiny obligate intracellular bacterium. "Obligate intracellular" means it cannot survive or reproduce on its own outside of a living cell — it must hijack the energy machinery inside your cells to function, because it cannot make its own ATP (the cell's fuel currency).

Here is the most important thing to know: the vast majority of people with chlamydia have no symptoms at all. An estimated 70–75% of women and 50% of men with chlamydia never feel sick. This is precisely why it spreads so widely — people do not know they have it, do not seek treatment, and unknowingly pass it on to partners. Regular testing is the only reliable way to know your status.

The excellent news is that chlamydia is easily and completely curable with a short course of antibiotics. There is no long-term infection to manage, no lifelong treatment, no chronic condition — just a one-week course of pills and it is gone. The risk comes only from untreated or repeatedly reinfected chlamydia, which can cause serious reproductive damage over time. Getting tested and treated early eliminates that risk entirely.

The CDC estimates more than 4 million new chlamydia infections occur in the United States every year, though only about 1.6 million are reported (because most people are never tested). Globally, the World Health Organization estimates 127 million new cases annually.

Back to Table of Contents

Epidemiology

Chlamydia is far more common than most people realize. The CDC's 2021 Surveillance Report recorded 1,644,416 reported cases in the United States — a deliberate undercount, since most people with chlamydia are never tested. Surveillance models estimate the true burden is closer to 4 million infections per year in the US alone.

Key patterns in who is most affected:

Globally, the WHO estimates 127 million new chlamydia infections each year, making it the most prevalent curable STI worldwide. Rates are highest in sub-Saharan Africa, South and Southeast Asia, and Latin America.

Transmission occurs through vaginal, anal, and oral sex. Chlamydia can also pass from mother to newborn during vaginal delivery, causing neonatal eye infection and pneumonia. It is not transmitted by casual contact — toilet seats, sharing food, swimming pools, or similar exposures do not spread chlamydia.

Back to Table of Contents

Pathophysiology

Chlamydia trachomatis has a fascinating and unusual two-stage life cycle that explains both how it infects you and why antibiotics must be taken for a full course:

The Biphasic Life Cycle

Stage 1 — Elementary bodies (EBs): These are the tiny, metabolically dormant, infectious particles that travel between people. Think of them like seeds — small, tough, ready to cause infection, but not yet active. EBs cannot replicate; their only job is to find and enter a new host cell. They attach to the columnar epithelial cells that line the cervix, urethra, rectum, and conjunctiva — and get drawn inside the cell through a process called endocytosis.

Stage 2 — Reticulate bodies (RBs): Once safely inside the host cell within a membrane-bound compartment called an inclusion, elementary bodies transform into reticulate bodies — larger, metabolically active, rapidly dividing forms. RBs steal the cell's ATP and nutrients to fuel their own replication over 48–72 hours. When the inclusion is packed with new organisms, RBs convert back into elementary bodies, the cell bursts open (lysis), and hundreds of new EBs are released to infect neighboring cells.

Why This Matters Clinically

Because chlamydia lives inside cells inside a protective inclusion, the immune system has a harder time reaching it — which is partly why infections persist unnoticed for weeks or months. The body's Th1 immune response (particularly interferon-gamma, or IFN-γ) eventually limits infection, but in repeated or prolonged infections, the inflammatory response itself drives fibrotic scarring in the fallopian tubes and reproductive organs. This scar tissue is permanent — the bacterium is gone but the damage remains. This is the mechanism behind chlamydia-associated infertility and ectopic pregnancy.

Serovars D–K target urogenital and ocular mucosal surfaces. A separate set of serovars (L1, L2, L3) cause a distinct and more invasive disease called Lymphogranuloma Venereum, covered in its own section below.

Back to Table of Contents

Sites of Infection and Clinical Presentation

Where chlamydia infects and what symptoms (if any) it causes depends on the site of exposure:

Asymptomatic Majority

70–75% of women and approximately 50% of men have no symptoms at all. This is not unusual — it is the rule, not the exception. Feeling fine does not mean you are infection-free. This is why annual testing for sexually active young women and regular testing for MSM are so important.

Urethral Infection (Men)

When symptoms appear in men, they typically start 7–21 days after exposure and may include a mild burning or stinging sensation while urinating (dysuria), and a thin, watery, or slightly cloudy urethral discharge. This discharge is typically much milder and less obviously purulent than the thick, yellow-green discharge characteristic of gonorrhea. Many men dismiss these mild symptoms or attribute them to other causes.

Cervical Infection (Women)

When chlamydia infects the cervix, it can cause mucopurulent cervicitis — inflammation with a yellowish discharge from the cervical opening. Women may notice an increase in vaginal discharge or spotting after sex. More often, there are no symptoms at all. The absence of symptoms does not mean the infection is absent or harmless.

Rectal Infection

Rectal chlamydia is common in MSM and in women who have receptive anal sex, and it is almost always asymptomatic. When symptoms occur, they include rectal pain, discharge, and a sensation of incomplete bowel emptying (tenesmus) — a syndrome called proctitis. Rectal chlamydia is frequently missed because providers do not always test this site even when urogenital results are negative.

Pharyngeal (Throat) Infection

Pharyngeal chlamydia from oral sex is uncommon and almost universally asymptomatic. It is rarely a source of ongoing transmission but should be tested in MSM who report receptive oral sex.

Ocular Infection

Adults can develop inclusion conjunctivitis (eye infection) from chlamydia through autoinoculation — touching infected genitals and then touching the eye. Symptoms include redness, discharge, and irritation that resembles ordinary pink eye but does not respond to standard eye drops. More significantly, chlamydia is the leading cause of neonatal conjunctivitis worldwide. Newborns passing through an infected birth canal can develop eye infection 5–12 days after birth. Without treatment, neonatal chlamydial conjunctivitis can cause corneal scarring.

Reactive Arthritis

About 1–3% of men with urethral chlamydia develop reactive arthritis — an immune-mediated joint inflammation triggered by the infection but not caused by bacteria in the joint itself. The classic triad is arthritis (usually large joints of the lower limbs), urethritis, and conjunctivitis or uveitis. It is more common in people with the HLA-B27 gene variant. The arthritis can be painful and debilitating and may persist for months. Treatment focuses on anti-inflammatory medications; antibiotics treat the underlying infection but do not reliably resolve the arthritis once it has started.

Back to Table of Contents

Lymphogranuloma Venereum (LGV)

Lymphogranuloma Venereum (LGV) is caused by C. trachomatis serovars L1, L2, and L3 — a biologically distinct set from the urogenital serovars D–K. LGV is far more invasive, spreading from the initial infection site into the lymphatic system.

Classic presentation (three stages):

  1. Primary stage: A small, painless genital ulcer or papule appears 3–30 days after exposure. It heals on its own and is often missed entirely.
  2. Secondary stage: 2–6 weeks later, painful swelling of the inguinal (groin) lymph nodes develops — these swollen nodes are called buboes. The overlying skin may become inflamed and the nodes may rupture and drain. Women and MSM may not develop inguinal buboes but instead develop deep pelvic or perirectal lymphadenopathy.
  3. Tertiary stage (if untreated): Chronic genital ulceration, rectal stricture (narrowing), fistulas, and elephantiasis of the genitals from lymphatic obstruction.

LGV proctitis in MSM: LGV is re-emerging in the United States and Europe, primarily among MSM. It commonly presents as severe proctocolitis — rectal pain, bloody discharge, and tenesmus — that can mimic inflammatory bowel disease. Standard chlamydia NAATs detect LGV, but distinguishing LGV serovars from D–K requires specialized testing at reference laboratories.

Treatment: Doxycycline 100 mg twice daily for 21 days (three times the course for standard urogenital chlamydia). Early treatment is highly effective; advanced fibrotic complications may require surgical intervention.

Back to Table of Contents

Complications

Untreated or repeatedly reinfected chlamydia can cause serious, permanent damage — primarily to the female reproductive system. This is why testing and early treatment matter so much.

Pelvic Inflammatory Disease (PID)

When chlamydia ascends from the cervix into the uterus and fallopian tubes, it causes PID — a spectrum of upper genital tract infection that includes endometritis (uterine inflammation), salpingitis (fallopian tube inflammation), and potentially tubo-ovarian abscess. An estimated 10–15% of untreated cervical chlamydia infections progress to PID. PID may cause pelvic pain and fever, or it may be completely silent ("silent PID") — discovered only when investigating infertility.

Tubal Factor Infertility

Each episode of PID causes inflammation and scarring in the fallopian tubes. Scar tissue blocks or distorts the tubes, preventing eggs from reaching the uterus or sperm from reaching eggs. The risk compounds with repeated infections:

Ectopic Pregnancy

Tubal scarring does not always fully block the tube — sometimes it narrows the tube enough that a fertilized egg cannot pass through to the uterus but can still implant in the tube itself. This ectopic (tubal) pregnancy is life-threatening without emergency treatment. Women with a history of chlamydia or PID have a 6–10 times higher risk of ectopic pregnancy than uninfected women.

Epididymo-Orchitis in Men

Untreated urethral chlamydia can spread upward to the epididymis (the coiled tube behind the testicle), causing epididymitis or epididymo-orchitis. Symptoms include unilateral scrotal pain, swelling, and tenderness. In young sexually active men, chlamydia is the most common cause. Rarely, severe or untreated epididymitis can affect fertility.

Neonatal Complications

Newborns infected during delivery face two main risks:

Increased HIV Susceptibility

Genital chlamydial infection causes mucosal inflammation and recruits CD4+ T cells and macrophages to the genital tract — the very cells HIV targets. This significantly increases the risk of both acquiring and transmitting HIV during co-infection. Treating chlamydia reduces HIV risk.

Back to Table of Contents

Diagnosis

Modern chlamydia testing is fast, highly accurate, and in many cases can be done with a self-collected sample — no pelvic exam required.

NAAT — the Gold Standard

Nucleic acid amplification tests (NAATs) detect chlamydia DNA or RNA directly from the sample. They offer very high sensitivity (greater than 95%) and specificity — meaning they almost never miss a real infection or falsely flag someone as positive. NAATs have replaced older methods (culture, enzyme immunoassay) in virtually all clinical settings.

Sample Types

Who Should Be Screened

Current CDC and USPSTF recommendations:

Other Diagnostic Points

Culture is no longer used in clinical practice (it is technically demanding, takes days, and is less sensitive than NAAT). It is occasionally used in forensic settings (such as sexual assault evaluations) because it provides definitive proof of viable organisms. Point-of-care NAATs that give results within 30–90 minutes are now commercially available and increasingly used in community settings and clinics without laboratory infrastructure.

Back to Table of Contents

Treatment

Chlamydia is completely curable with antibiotics. The 2021 CDC STI Treatment Guidelines updated the preferred regimen — here is what you need to know:

Current First-Line Regimen (CDC 2021)

Doxycycline 100 mg orally twice daily for 7 days is now the preferred treatment for chlamydia in all non-pregnant adults, including rectal chlamydia. This replaced azithromycin as the first-line recommendation.

Why the change? Multiple randomized trials showed that doxycycline significantly outperforms azithromycin for rectal chlamydia. Azithromycin's single-dose pharmacokinetics work well in urogenital tissue but achieve lower drug concentrations in rectal tissue. Doxycycline achieves higher and more sustained levels throughout the body. Since rectal chlamydia is common and often asymptomatic, doxycycline is now preferred to ensure treatment works regardless of which body site is infected.

Azithromycin — When It Is Still Used

Azithromycin 1 g orally in a single dose remains an acceptable alternative for urogenital chlamydia (not rectal) when adherence to a 7-day doxycycline course is a significant concern. The main advantage of azithromycin is that it is one pill taken once — useful in settings where directly observed therapy is possible or when a patient's life circumstances make completing a week of twice-daily pills unrealistic. The single dose also eliminates the risk of forgetting doses partway through. However, for most people, doxycycline is preferred.

Treatment in Pregnancy

Doxycycline is contraindicated in the second and third trimesters of pregnancy (it can affect fetal bone and tooth development). Options for pregnant patients:

LGV Treatment

Doxycycline 100 mg twice daily for 21 days — a three-times-longer course than standard chlamydia, because LGV invades lymphatic tissue more deeply.

Partner Treatment and Notification

All sexual partners from the past 60 days should be notified, tested, and treated. Most US states allow expedited partner therapy (EPT) — the infected person is given a prescription or medication to take directly to their partner(s) without the partner needing a clinic visit first. This significantly improves partner treatment rates. Check your state's laws at the CDC EPT legal status page.

Re-testing After Treatment

Routine test-of-cure is not recommended for non-pregnant adults who complete doxycycline treatment (the cure rate is over 97%). However, re-testing 3 months after treatment is recommended because reinfection is extremely common — most positive tests 3 months later represent a new infection from an untreated or newly exposed partner rather than treatment failure. Re-testing in pregnancy and for rectal LGV after treatment completion is recommended.

Antibiotic Resistance

Unlike gonorrhea, significant antibiotic resistance in C. trachomatis remains rare. Doxycycline resistance is not a current clinical concern. Monitoring continues, but chlamydia treatment does not face the urgent resistance crisis that gonorrhea treatment does.

Back to Table of Contents

Prevention

There is no vaccine for chlamydia, so prevention relies on behavioral strategies and regular testing:

Back to Table of Contents

Research Advances

Active research into chlamydia is addressing its persistence as the world's most common bacterial STI:

Vaccine Development

The first-in-human chlamydia vaccine trial (CTH522 adjuvanted with CAF01) was completed in 2021, showing that the vaccine was safe and induced mucosal and systemic immune responses. The CTH522 antigen targets the major outer membrane protein (MOMP). Ongoing challenges include the fact that natural chlamydia infection does not produce robust long-lasting immunity — meaning the vaccine must do better than natural infection, a difficult bar. Research is also exploring live attenuated vaccines and T-cell-focused approaches using the polymorphic membrane proteins (Pmps).

Point-of-Care Testing

Traditional NAATs require laboratory infrastructure and return results in 24–72 hours. New rapid NAAT platforms (GeneXpert, Binx io) deliver results in 30–90 minutes at the point of care. This transforms management: a patient can be tested, diagnosed, and treated in a single visit, eliminating the problem of lost-to-follow-up patients who never receive their positive result. Point-of-care testing is particularly valuable in low-resource settings and community-based testing programs.

Doxycycline PEP

The DoxyPEP trial published in 2022 (Luetkemeyer et al., NEJM) demonstrated that doxycycline 200 mg taken within 72 hours of condomless sex reduced chlamydia incidence by 88% in MSM and transgender women. This represents one of the most significant advances in bacterial STI prevention in decades. Questions remain about long-term antibiotic resistance selection in gut microbiome organisms, which is being actively monitored.

Genomic Epidemiology

Whole-genome sequencing of C. trachomatis is increasingly used to track transmission networks, identify outbreak clusters, and detect the emergence of antibiotic resistance mutations before they become clinically widespread. This real-time genomic surveillance is reshaping public health responses to chlamydia outbreaks.

Understanding Persistent Infection

Under certain stress conditions (interferon-gamma exposure, antibiotic sub-inhibitory concentrations, nutrient deprivation), chlamydia can enter a persistent, aberrant state — forming enlarged, non-dividing inclusions sometimes called "aberrant bodies." Whether this in-vitro persistence translates to clinical treatment failures is debated, but it may explain rare cases where infection seems to recur without documented re-exposure.

Back to Table of Contents

Key Research Papers

  1. Workowski KA et al., 2021 — CDC STI Treatment Guidelines. MMWR Recomm Rep. PMID: 34292926
  2. Workowski KA, Bolan GA, 2015 — CDC STD Treatment Guidelines. MMWR Recomm Rep. PMID: 25621840
  3. Manhart LE et al., 2020 — Doxycycline vs azithromycin for rectal chlamydia treatment. Clin Infect Dis. PMID: 31774571
  4. Scholes D et al. — Chlamydia screening effectiveness and prevention of PID. PMID: 29340561
  5. Luetkemeyer AF et al., 2023 — Doxycycline postexposure prophylaxis (DoxyPEP) for STI prevention. NEJM. PMID: 35512687
  6. Poston TB, Darville T, 2018 — Chlamydia trachomatis: pathogenesis, immunity, and vaccine development. Curr Opin Infect Dis. PMID: 28922337
  7. PubMed: chlamydia NAAT diagnostic accuracy
  8. PubMed: chlamydia PID infertility risk
  9. PubMed: chlamydia CTH522 vaccine trial
  10. PubMed: lymphogranuloma venereum LGV treatment MSM
  11. PubMed: chlamydia screening recommendations USPSTF women
  12. PubMed: reactive arthritis chlamydia HLA-B27

Back to Table of Contents

  1. Chlamydia epidemiology United States
  2. Chlamydia intracellular life cycle
  3. Chlamydia obligate intracellular pathogen
  4. Doxycycline chlamydia treatment outcomes
  5. Azithromycin rectal chlamydia treatment failure
  6. Chlamydia ectopic pregnancy tubal damage
  7. Chlamydia in pregnancy neonatal complications
  8. Asymptomatic chlamydia screening importance
  9. Expedited partner therapy STI outcomes
  10. Chlamydia HIV co-infection susceptibility
  11. Doxycycline PEP STI prevention MSM
  12. Point-of-care chlamydia NAAT rapid test

Back to Table of Contents

Connections

Back to Table of Contents